Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial resultsKelly C. Goldsmith, Yaël P. Mossé, Julie R. Park et al.|Nature Medicine|2023Cited by 125
2024 Update of the North American Consensus Guidelines for Pediatric Administered Radiopharmaceutical ActivitiesS. Ted Treves, Katherine Zukotynski, Christiane Sarah Burton et al.|Journal of Nuclear Medicine Technology|2025Cited by 97